Ischemix

9 articles about Ischemix

• Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

  8/25/2023

  Ischemix, Inc., a privately-held company focused on developing cytoprotective therapeutics for serious medical conditions, today announced that it has completed an 80-subject Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetics of its drug candidate, CMX-2043, in healthy human subjects.

• Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

  7/7/2021

  Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, announced that the US Department of Defense has made a $2.9 award to the Company to fund a Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI.

• Ischemix Elects Peter G. Milner, MD To Board Of Directors

  8/12/2015

• Ischemix Announces That Safety Review Committee For CARIN Trial Recommends Phase 2a Study To Continue As Planned

  5/20/2015

• Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury

  6/26/2014

• Clinical-Stage Biotech Ischemix Taps DeWahl as CEO

  1/10/2013

• Ischemix Announces Positive Top Line Data from Phase 2 Clinical Trial of CMX-2043

  6/17/2011

• Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury

  3/9/2010

• Ischemix Appoints Robert DuFresne as Chief Executive Officer

  3/24/2009